Trial Profile
A double-blind placebo-controlled study of the efficacy and safety of the P38 map kinase inhibitor SB681323 in patients with neuropathic pain following nerve trauma
Status:
Active, no longer recruiting
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 04 Dec 2006
Price :
$35
*
At a glance
- Drugs Dilmapimod (Primary)
- Indications Neuropathic pain
- Focus Therapeutic Use
- 04 Dec 2006 New trial record.